| May 2026 | Significant alterations in endometrial protein expression during ovarian stimulation cycles in women with poor ovarian response suggest potential biomarkers linked to implantation and endometrial receptivity. Sciomics supported the study with protein profiling of human endometrial biopsy tissue usingthe scioDiscover affinity proteomics platform.
| March 2026 | Inflammatory reprogramming of stromal chemokine networks drives tissue disorganisation and disease progression in nodal B cell lymphoma. Sciomics supported the study with secretome profiling of human iFRC supernatant samples using the scioCD affinity proteomics platform.
| March 2026 | The HDAC inhibitor fimepinostat effectively induces apoptosis and suppresses tumor cell proliferation, highlighting its potential as a therapeutic strategy for schwannoma.
Sciomics supported the study with proteomic profiling and post-translational modification analysis of human cell samples.
| March 2026 | GPRC5D loss promotes immunotherapy resistance and aggressive multiple myeloma growth, supporting early monitoring and dual-targeted treatment strategies. Sciomics supported the study with cytokine profiling of human OPM-2 supernatant samples using the scioCyto affinity proteomics platform.
| February 2026 | Patient-derived striatum organoids carrying the LRRK2-G2019S mutation reveal early Parkinson’s Disease features, including neuroinflammation and altered signalling. Sciomics supported the study by analysing patient-derived striatum organoids using the scioDiscover proteomic microarray.
| April 2023 | New Article: In a protein biomarker development project initiated by Sciomics, we have identified protein biomarker panels predicting development of a severe Covid.19 disease.
| October 2022 | Dapr. protects against induced kidney toxicity and anemia by preventing protein phosphorylation changes, preserving microcirculation, and maintaining hemoglobin levels.
Sciomics contributed to this study by analyzing mouse kidney samples using the scioPhospho proteomic assay.
| May 2022 | In a study by Maja Pušić et al. Cycle-dependent plasma protein biomarkers for peritoneal endometriosis were identified by our scioDiscover platform.
| February 2023 | New Article: In the study Tintelnot et al. identified a microbiota-derived metabolite that has clinical implications in the treatment of pancreatic cancer. Sciomics supported the authors by a protein profiling study of tumours derived from a mouse model upon treatment with 3-IAA and Firinox.
Page 5 of 10
PD Dr. med. Mascha O. Fiedler-Kalenka and Dr. med. Benjamin Seybold
Heidelberg University Hospital, Department of Anesthesiology, Heidelberg, GermanyGerman Center for Lung Research (DZL), Translational Lung Research Center Heidelberg (TLRC), Heidelberg, Germany
"From the very beginning, working with the friendly and highly competent team at Sciomics was both professional and refreshingly straightforward. We particularly valued their openness to our specific research questions and the expert support they provided in planning and interpreting our exploratory cytokine analysis in a preclinical lung injury model. Communication was always on equal footing, enriched by Sciomics’ deep expertise, which also sparked new ideas for future projects."
Product: scioCD
Tara Sigdel, PhD
Associate Professor, Department of Surgery, University of California San Francisco
"We collaborated with Sciomics GmbH in Germany to analyze proteomics data from blood samples of kidney transplant recipients and liver perfusates during normothermic machine perfusion. Throughout the process, Sciomics provided exceptional support, ensuring timely data delivery and valuable assistance with data analysis. Their expertise and commitment have been instrumental in advancing our research, and we are currently using their data in multiple manuscript submissions. I highly recommend Sciomics for their reliable service and expertise in proteomics."
Product: scioDiscover